Transgene’s Combined General Meeting of May 15, 2024

Strasbourg, France, May 15, 2024, 05:45 p.m. CEST – The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held today (May 15, 2024) at 10:00 a.m. at the Company’s headquarters (400 boulevard Gonthier d’Andernach – Parc d’Innovation – 67400 Illkirch-Graffenstaden, France).

The meeting was chaired by Alessandro Riva, Chairman and CEO, to approve the Company’s financial statements for the year ended December 31, 2023, and to vote on the other resolutions submitted for approval.

The replay of the Combined General Meeting is available via Transgene’s website and here.  

The Combined General Meeting adopted all resolutions recommended by the Board of Directors.

The Combined General Meeting notably has appointed one new director, Michel Baguenault de Puchesse, as non-independent director.

Michel Baguenault de Puchesse brings to the Board of Directors his expertise in legal, financial and human resources matters as well as in corporate organization and governance. Michel has been CEO of Institut Mérieux since January 2020. Prior to this position, Michel held several positions within the Institut Mérieux group: Executive Vice President of Institut Mérieux (2009 – 2011), Corporate Vice President, HR and Communication of bioMérieux (2011 – 2016), Secretary General of bioMérieux, in charge of Human Resources, Communication, Audit - Risks & Compliance, and Protocol (2016 – 2020).

Before joining Institut Mérieux, he was Financial Strategy Advisor at Financière Meeschaert, from 1996 to 2004, and Head of Development at Banque Martin Maurel in Lyon, from 2004 to 2008.

Michel Baguenault de Puchesse is a graduate from EM LYON Business School and holds a Law degree.

Within the Institut Mérieux Group, Michel Baguenault de Puchesse is a board member of Institut Mérieux, Mérieux NutriSciences, Fondation Christophe & Rodolphe Mérieux, and non-executive President of Mérieux Equity Partners.

Outside the Group, he is board member of CIC Lyonnaise de Banque, Descours & Cabaud SA, Mutuelles AXA, Siparex / Sigefi, Fondation Solidarités by Crédit Agricole. He also joined the supervisory board of Unibel.

Transgene’s Board of Directors is now comprised of the following members:

• Dr. Alessandro Riva, Chairman;
• Alain Mérieux, Honorary Chairman;
• Philippe Archinard, Director;
• Michel Baguenault de Puchesse, Director;
• Jean-Luc Bélingard, Director;
• Prof. Jean-Yves Blay, independent Director;
• Sandrine Flory, Director (TSGH representative);
• Benoît Habert, independent Director;
• Marie Landel, independent Director;
• Maya Saïd, independent Director;
• Carol Stuckley, independent Director.

The Board is now composed of 10 members. In terms of independence and diversity, the Board of Directors is compliant with the applicable rules, namely: 4 independent directors out of 10, i.e. 40%, and 4 women out of 10, i.e. a parity of 40%.